AstraZeneca, a global pharmaceutical company, has stated plans to build a$ 1.5 billion manufacturing facility in Singapore for antibody drug conjugates ( ADCs ), in order to increase the global supply of its ADC portfolio, according to a May 20 media release.
ADCs are the newest treatments that use a targeted antibody to deliver cancer-killing agents instantly to cancer cells. The production of ADCs is a multiple- step process that includes antibodies manufacturing, production of chemotherapy drug and linker, conjugation of drug- linker to the antibody, and filling of the completed ADC substance.
AstraZeneca wants to start building the manufacturing service by the end of 2024, with a goal of functional preparation starting in 2029. AstraZeneca added that it will collaborate with the government of Singapore and other parties to develop efficient solutions for the ADC service. The service will be constructed to produce no coal from its first time of operation.
The planned new service is supported by the Singapore Economic Development Board ( EDB), and it will be AstraZeneca’s second “end- to- end” ADC manufacturing site.
EDB’s president Png Cheong said in the discharge:” We welcome AstraZeneca’s decision to establish a manufacturing appearance in Singapore for the first time. AstraZeneca will also have a first in the world by having an end-to-end manufacturing facility for book antibodies drug conjugates that enable precise cancer treatments.
Cheong continued,” This new purchase is a powerful show of confidence in Singapore’s biotech production capabilities and talent, strengthens our ecosystem in supporting the development and manufacturing of precision medicines, and creates important jobs and economic opportunities for Singapore. We look forward to a successful relationship with AstraZeneca”.
Pascal Soriot, chief executive officer, AstraZeneca, said:” Singapore is one of the country’s most beautiful countries for funding given its reputation for excellence in difficult production, and I’m excited for AstraZeneca to find our$ 1.5 billion ADC production facility in the country”.
AstraZeneca has a broad portfolio of in- house ADCs, including six wholly owned ADCs, and “many more” in preclinical development, the release said.
¬ Haymarket Media Limited. All rights reserved.